NCT01421524 2023-12-12
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
Phase 1 Completed
Clinical Trials
9 trialsNCT01572493 2023-03-06
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01644968 2022-05-17
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
Providence Health & Services
Phase 1 Completed
NCT01353625 2021-10-05
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
Phase 1 Completed
NCT01916135 2020-04-27
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02192346 2018-08-17
α-TEA in Advanced Cancer
Providence Health & Services
Phase 1 Completed
NCT01026415 2014-12-18
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Seagen Inc.
Phase 1 Completed
NCT01479023 2013-12-20
Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
Washington University School of Medicine
Phase 1 Terminated
NCT00466583 2011-07-07
Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma
Enzon Pharmaceuticals, Inc.
Phase 1 Completed